Infectious Diseases Market Size, Share, Trends, Industry Analysis, and Forecast (2024 – 2030)

Infectious Diseases Market Size
The global infectious diseases market size was valued at $21.85 billion in 2024 and is projected to reach $31.89 billion by 2030, growing at a CAGR of 6.5% during the forecast period.

Infectious Diseases Market Overview
Infectious diseases are health disorders caused by pathogenic organisms such as bacteria, viruses, fungi, and parasites that invade the body, often leading to significant illness. These diseases can be transmitted through various means, including direct contact with infected individuals, contaminated food or water, and bites from infected animals. The symptoms of infectious diseases can vary widely, ranging from mild manifestations like fever and fatigue to severe conditions requiring hospitalization. The global burden of infectious diseases is substantial, impacting public health systems and economies, particularly in vulnerable populations. 

Companies can benefit from the infectious disease landscape in several ways. For instance, pharmaceutical and biotechnology firms can develop vaccines and treatments, addressing both existing and emerging infectious diseases, which can lead to substantial financial returns and improved public health outcomes. Additionally, businesses involved in diagnostics and health technology can capitalize on the need for rapid testing and monitoring solutions. The ongoing demand for effective prevention and treatment strategies in infectious diseases presents opportunities for innovation and growth in healthcare sectors.

Infectious Diseases Market Dynamics
The infectious diseases market is expected to witness significant growth in the future due to increasing prevalence of infectious diseases, growing awareness of preventive measures, and rising demand for rapid diagnostic solutions. However, high costs associated with advanced diagnostic tests and the lack of access to healthcare facilities are restraining the growth of the market.

Furthermore, expansion of diagnostic testing, development of multiplex assays, and increasing focus on personalized medicine are the key trends propelling the infectious diseases market.

Increasing Prevalence of Infectious Diseases is driving the Infectious Diseases Market
The increasing prevalence of infectious diseases is significantly impacting the infectious diseases market, driving demand for effective diagnostic solutions, treatments, and preventive measures. 
• For instance, the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to a surge in demand for rapid antigen tests, with companies like Abbott Laboratories launching their BinaxNOW COVID-19 Ag Card in August 2020. 
• Similarly, the increasing incidence of HIV/AIDS has spurred the development of new antiretroviral therapies, with ViiV Healthcare, a joint venture between GlaxoSmithKline, Pfizer, and Shionogi, receiving FDA approval for its long-acting injectable treatment Cabenuva in January 2021. 
Governments have also stepped up their efforts to combat infectious diseases, with the U.S. Centers for Disease Control and Prevention (CDC) allocating $1.75 billion in funding for genomic sequencing and surveillance of SARS-CoV-2 variants in February 2021. These examples demonstrate how the growing burden of infectious diseases is propelling innovation, investment, and collaboration across the pharmaceutical, diagnostic, and public health sectors to develop and deploy effective solutions to mitigate the impact of these diseases on global health and economies.

By End User, the Hospital/Clinical Laboratories Segment held the Larger Market Share, and it would continue on this Path during the Forecast Period
The hospital/clinical laboratories segment dominated the market share and is expected to maintain its leading position throughout the forecast period owing to the increasing prevalence of infectious diseases and the need for rapid and accurate diagnostic solutions. This growth is fueled by advancements in molecular diagnostics and the shift towards point-of-care testing, which allows for quicker diagnosis and treatment initiation. 
• Companies like Abbott have been pivotal in this shift; for instance, the launch of the ID NOW COVID-19 test in March 2020 provided rapid results within minutes, significantly aiding healthcare providers in managing the pandemic. 
• Similarly, Thermo Fisher Scientific expanded its infectious disease diagnostics portfolio by acquiring Mesa Biotech, enhancing its point-of-care molecular diagnostics capabilities.
Government initiatives also play a crucial role, with funding directed towards improving laboratory infrastructure and expanding testing capabilities. 
• For example, the U.S. government allocated substantial resources to enhance COVID-19 testing in hospitals, which has had lasting effects on the readiness of clinical laboratories to handle infectious disease outbreaks. These factors collectively contribute to the robust growth and positive impact of the infectious diseases market in hospital and clinical laboratory settings.

By Geography, North America Dominates by Being the Largest Market for Infectious Diseases
North America leads as the primary market for infectious diseases during the forecast period due to the high prevalence of infectious diseases, advanced healthcare infrastructure, and significant government initiatives aimed at disease control and prevention. Companies like Abbott and Thermo Fisher Scientific are at the forefront of this growth, with Abbott launching its BinaxNOW COVID-19 antigen test in August 2020, which significantly contributed to rapid testing capabilities during the pandemic. 

Government initiatives, such as the CDC's funding of $1.75 billion in February 2021 for genomic sequencing to track SARS-CoV-2 variants, further emphasize the commitment to enhancing public health responses. Additionally, the U.S. healthcare system's emphasis on early diagnosis has led to increased investments in diagnostic technologies, with major players like bioMérieux and BD expanding their product lines to meet this demand. The combination of rising disease prevalence, technological advancements, and proactive government actions is positively impacting the infectious diseases market in North America, leading to improved health outcomes and economic benefits across the region.

Key Target Audience:
• Healthcare Providers
• Government Agencies
• Regulatory Authorities
• Research Institutions
• Non-Governmental Organizations (NGOs)
• Patients and Patient Advocacy Groups
• Public Health Organizations
• Contract Research Organizations (CROs)

List of the Key Players Profiled in the Report Includes:
• Abbott
• BD
• bioMérieux
• Bio-Rad Laboratories Inc
• Danaher
• DiaSorin S.p.A
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson Private Limited
• Meridian Bioscience Inc
• Quidel Corporation
• Siemens
• Thermo Fisher Scientific Inc

Recent Developments:
• In July 2023, BD launched its new BD MAX™ System, a molecular diagnostic platform designed to enhance the detection of infectious diseases, including sexually transmitted infections. This system aims to provide faster and more accurate results, thereby improving patient outcomes and public health responses.
• In June 2023, Bio-Rad announced the expansion of its portfolio with the introduction of new PCR reagents aimed at enhancing the detection of infectious diseases. These reagents are designed to improve the sensitivity and specificity of tests for various pathogens, supporting laboratories in their diagnostic capabilities
• In May 2023, bioMérieux announced the launch of its new molecular diagnostic test for the rapid detection of respiratory viruses, including COVID-19 and influenza. This test is designed to provide results in under an hour, facilitating timely clinical decision-making and improving patient management during respiratory illness outbreaks.

Market Segmentation:
The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Product and Services: 
• Kits and Reagents
• Instruments
• Services
• Software
• Assays

Market by, Technology:
• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Immunodiagnostics
• DNA Sequencing and Next-Generation Sequencing (NGS)
• DNA Microarray
• Clinical Microbiology
• Other Technologies

Market by, Disease Type:
• Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
• Hepatitis
• Hospital-Acquired Infections (HAIS)
• Human Immunodeficiency Virus (HIV)
• Human Papillomavirus (HPV)
• Influenza
• Tuberculosis (TB)
• Other Disease Types

Market by, End User: 
• Academic/Research Institutes
• Hospital/Clinical Laboratories
• Physician Offices
• Reference Laboratories
• Other End Users

Market by, Geography:
The infectious diseases market report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:
• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis
• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis
• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis
• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

The report offers insights into the following aspects:
• Analysis of major market trends, factors driving, restraining, threatening, and providing opportunities for the market.
• Analysis of the market structure by identifying various segments and sub-segments of the market.
• Understand the revenue forecast of the market for North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
• Analysis of opportunities by identification of high-growth segments/revenue pockets in the market.
• Understand major player profiles in the market and analyze their business strategies.
• Understand competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product launches in the market.

Table Of Content

1 Market Introduction            
    1.1 Market Definition         
    1.2 Research Scope and Segmentation       
    1.3 Stakeholders         
    1.4 List of Abbreviations        
               
2 Executive Summary             
               
3 Research Methodology            
    3.1 Identification of Data        
    3.2 Data Analysis         
    3.3 Verification         
    3.4 Data Sources         
    3.5 Assumptions         
               
4 Market Dynamics             
    4.1 Market Drivers         
    4.2 Market Restraints         
    4.3 Market Opportunities        
    4.4 Market Challenges         
               
5 Porter's Five Force Analysis            
    5.1 Bargaining Power of Suppliers        
    5.2 Bargaining Power of Buyers        
    5.3 Threat of New Entrants        
    5.4 Threat of Substitutes        
    5.5 Competitive Rivalry in the Market       
               
6 Global Infectious Diseases Market by, Product and Services         
    6.1 Overview         
    6.2 Kits and Reagents         
    6.3 Instruments         
    6.4 Services          
    6.5 Software          
    6.6 Assays          
               
7 Global Infectious Diseases Market by, Technology          
    7.1 Overview         
    7.2 Polymerase Chain Reaction (PCR)       
    7.3 Isothermal Nucleic Acid Amplification Technology (INAAT)     
    7.4 Immunodiagnostics         
    7.5 DNA Sequencing and Next-Generation Sequencing (NGS)     
    7.6 DNA Microarray         
    7.7 Clinical Microbiology        
    7.8 Other Technologies         
               
8 Global Infectious Diseases Market by, Disease Type         
    8.1 Overview         
    8.2 Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)    
    8.3 Hepatitis          
    8.4 Hospital-Acquired Infections (HAIS)       
    8.5 Human Immunodeficiency Virus (HIV)       
    8.6 Human Papillomavirus (HPV)        
    8.7 Influenza          
    8.8 Tuberculosis (TB)         
    8.9 Other Disease Types        
               
9 Global Infectious Diseases Market by, End User          
    9.1 Overview         
    9.2 Academic/Research Institutes        
    9.3 Hospital/Clinical Laboratories        
    9.4 Physician Offices         
    9.5 Reference Laboratories        
    9.6 Other End Users         
               
10 Global Infectious Diseases Market by, Geography          
    10.1 Overview         
    10.2 North America         
             10.2.1 US 
             10.2.2 Canada 
             10.2.3 Mexico 
    10.3 Europe          
             10.3.1 Germany 
             10.3.2 France 
             10.3.3 UK 
             10.3.4 Italy 
             10.3.5 Spain 
             10.3.6 Rest of Europe
    10.4 Asia Pacific         
             10.4.1 China 
             10.4.2 Japan 
             10.4.3 India 
             10.4.4 South Korea
             10.4.5 Australia 
             10.4.6 New Zealand
             10.4.7 Rest of Asia Pacific
    10.5 South America         
             10.5.1 Brazil 
             10.5.2 Argentina
             10.5.3 Chile 
             10.5.4 Rest of South America
    10.6 Middle East & Africa        
             10.6.1 UAE 
             10.6.2 Saudi Arabia
             10.6.3 Qatar 
             10.6.4 Iran 
             10.6.5 South Africa
             10.6.6 Rest of Middle East & Africa
               
11 Key Developments             
               
12 Company Profiling             
    12.1 Abbott          
             12.1.1 Business Overview
             12.1.2 Product/Service Offering
             12.1.3 Financial Overview
             12.1.4 SWOT Analysis
             12.1.5 Key Activities
    12.2 BD          
    12.3 bioMérieux         
    12.4 Bio-Rad Laboratories Inc        
    12.5 Danaher          
    12.6 DiaSorin S.p.A         
    12.7 F. Hoffmann-La Roche Ltd        
    12.8 Johnson and Johnson Private Limited       
    12.9 Meridian Bioscience Inc        
    12.10 Quidel Corporation         
    12.11 Siemens          
    12.12 Thermo Fisher Scientific Inc